89 articles - From Friday May 02 2025 to Friday May 09 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Am J Gastroenterol |
|---|
ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease. Level of evidence and strength of recommendations were evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations system. This guideline was developed under the auspices of the American College of Gastroenterology Practice Parameters Committee. |
| Clin Gastroenterol Hepatol |
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Clinical Trial: Effect of a 28-Day Low FODMAP Diet on Gastrointestinal Symptoms Associated With Endometriosis (EndoFOD)-A Randomised, Controlled Crossover Feeding Study. The low FODMAP diet ameliorates gastrointestinal symptoms related to endometriosis and improves quality of life. Confirmation of these findings in a real-world setting is required. |
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU. In this extended analysis of patients included in the EXIT trial, withdrawing anti-TNF therapy in patients with IBD in remission was not associated with a higher long-term relapse risk. |
| Am J Gastroenterol |
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease. In a randomized trial of children with CD initiating anti-TNFα, 40% were HLA DQ-A1*05 positive, which was associated with a trend toward increased risk of both treatment failure and ADA. These risks were mitigated, but not eliminated, by adding oral methotrexate. HLA DQ-A1*05 is an important biomarker for prognosis and risk stratification. |
| Clin Gastroenterol Hepatol |
Cost-effectiveness of Lynch syndrome screening in colorectal cancer: universal germline vs sequential screening. Current clinical practice is cost-ineffective. Prospective intervention to dramatically increase LS testing (i.e., to reach a threshold of >75%) or, if this level cannot be reached, upfront germline testing are cost-effective interventions that improve quality-adjusted life expectancy. |
Detection of Barrett's Esophagus Prior to Development of Esophageal and Esophagogastric Junction Adenocarcinoma. IM appears required for development of EAC and likely EGJAC. EGD with biopsy had only modest rate for detecting a precursor state for subsequent adenocarcinoma and was lower for S2 compared to S1. Variability in endoscopic suspicion, including segments <1cm are potential areas for improvement in detection of BE by EGD. |
| Gastroenterology |
Artificial Intelligence in Biliopancreatic Disorders: Applications in Cross-Imaging and Endoscopy. Promising applications in biliopancreatic endoscopy include the detection of biliary stenosis, classification of dysplastic precursor lesions, and assessment of pancreatic abnormalities. This review aims to capture the current state of artificial intelligence application in biliopancreatic disorders, summarizing the results of early studies, and paving the path for future directions. |
Gene-specific detection rate of adenomas and advanced adenomas in Lynch syndrome. Carriers of MLH1/MSH2 pathogenic variants are at a higher risk of developing AAs compared to those with MSH6/PMS2 mutations, with MSH6 carriers exhibiting an intermediate risk profile. AAs are an independent risk factor for PCCRC. Lynch syndrome patients with AAs should be identified as high-risk and undergo enhanced colonoscopy surveillance. |
Inadequate Propulsion and Pelvic Floor Relaxation in Dyssynergic Defecation: Insights from Synchronous Proctomanometry. Early events - increased rectal pressure (propulsive force), anorectal angle (puborectalis relaxation), and anorectal descent (perineal relaxation) - determine evacuation. Body position and rectal filling affect the rectoanal gradient. Most DD patients have both impaired propulsion and relaxation. Constipated patients with a prolonged BET and/or reduced evacuation have DD. |
| Gastrointest Endosc |
Improved clinical outcomes of patients with cirrhosis and acute variceal bleeding over the last two decades. Recurrent bleeding and mortality rates after AVB improved over the last two decades but remain substantial, highlighting the need for continued efforts to optimize outcomes for patients with cirrhosis. |
| Gut |
Microbiota fasting-related changes ameliorate cognitive decline in obesity and boost ex vivo microglial function through the gut-brain axis. Fasting-induced modifications in gut microbiota contribute to cognitive improvement in individuals with obesity, with microglial cells playing a crucial mediatory role. Among the interventions, ADF most effectively enhanced microglial function and cognitive performance, suggesting its potential as a therapeutic strategy for obesity-related cognitive decline. Further studies are required to fully elucidate the underlying mechanisms. |
| Hepatology |
Altered blood-brain barrier permeability is associated with abnormal distant connectivity and regional homogeneity in covert hepatic encephalopathy - a cross sectional study. There was a strong association between disrupted blood-brain barrier (BBB) integrity and attenuated functional connectivity, with reductions in functional connectivity within the DMN and Frontoparietal Network (FPN), circuits closely linked to executive control. This attenuation was evident both in local regional and in distant connectivity within these networks. |
Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction. Of the 10 investigated NITs, MAF-5 discriminated best between al conditions except cirrhosis, for which SAFE yielded the highest accuracy. The performance of FIB-4 was poor, implying that referral pathways for significant liver disease in low-prevalence populations can be improved when more accurate NITs such as MAF-5 are employed. |
Hepatic stellate cell heterogeneity: Functional aspects and therapeutic implications. We explore the spatiotemporal diversity of HSCs, highlighting their subpopulations and their specialized roles, as well as the complex bidirectional communications between HSCs, hepatocytes, endothelial cells, macrophages/monocytes, T cells, and tumor cells. By integrating insights from single-cell sequencing, spatial transcriptomics, preclinical data and clinical data, this review aims to provide an updated understanding of how HSC heterogeneity contributes to liver homeostasis and disease and can be targeted for therapeutic purposes. |
Metabolic reprograming of immune cells in MASH. However, research on the metabolic characteristics of other types of immune cells remains limited. With the development of single-cell genomics and animal models of MASH, we anticipate that further studies in this compelling field may shed light on the pathogenesis of MASH and pave the way for novel therapeutic strategies. |
Organ damage proteomic signature identifies patients with MASLD at-risk of systemic complications. Our study provides a framework for potential mechanisms associated with systemic diseases that facilitates holistic management by stratifying patients with MASLD into subclasses at-risk of extrahepatic manifestations. |
| J Hepatol |
High inherited risk predicts age-associated increases in fibrosis in patients with MASLD. GRS, PRS-HFC, PRS-5, and PNPLA3 genotypes alone are associated with greater fibrosis per decade, resulting in divergent disease trajectories starting in midlife. Assessing genetic risk in MASLD will identify high-risk patients who require more frequent monitoring. Impact and implications This study provides granular evidence that genetic predisposition, particularly the PNPLA3 G/G genotype, significantly influences the trajectory of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), with a more pronounced impact emerging after the fourth decade of life. These findings highlight the importance of incorporating genetic risk assessment into MASLD management, as it allows for the early identification of high-risk individuals who may benefit from more frequent monitoring and targeted interventions. Given the rising global burden of MASLD, clinicians, researchers, and policymakers should consider integrating genetic stratification into existing risk assessment frameworks to refine screening and surveillance strategies. By optimizing patient selection for non-invasive fibrosis assessment and potential therapeutic interventions, this approach could enhance precision medicine efforts and may improve long-term outcomes. |
New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas. Aurkines represent promising therapeutic drugs for both naïve and cisplatin-resistant cancers due to their unique polyelectrophilic properties and selective targeting of malignant cells. Impact and implications This study introduces a novel therapeutic strategy designed to induce frequent double-strand DNA breaks selectively in both naïve and cisplatin-resistant cancer cells, without evident toxic side effects at therapeutic doses. This approach may settle the basis for new strategies to overcome the critical challenge of drug resistance in cancer treatment, and has the potential to be a breakthrough not only for the treatment of biliary tumors but also for other cancers. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review. Evidence for medical therapies for joint, skin and eye EIMs in IBD is heterogeneous and of low quality. Further research is needed, including a multidisciplinary approach and novel and practical methods for endpoint evaluation. |
| Gastroenterology |
Advances in Locoregional and Systemic Treatments for HCC. These improved outcomes raise several new questions including which patients with liver-localized HCC should receive systemic therapy, how should this be sequenced or combined with other available therapies, and how to manage those patients with marked responses, including consideration of liver transplantation. These questions are often determined on a case-by-case basis and best made in a multidisciplinary manner, considering several factors including tumor burden, degree of liver dysfunction, performance status, and patient's long-term goals of care. |
| Gastrointest Endosc |
| J Hepatol |
Combined Liver with Other Solid Organ Transplants: Promises, Pitfalls and ethical dilemmas, An Expert Opinion. Immunological advantages, advanced risk assessments, and novel technologies, such as machine perfusion, improve success rates. The opinion calls for harmonized policies to address disparities in organ allocation while maintaining equitable access and optimized outcomes. |
Hepatocellular carcinoma in people living with HIV. Furthermore, whether the biology of the tumour and its microenvironment is influenced by HIV and affects response to treatment is incompletely understood. In this review we summarise the current understanding of pathophysiology, screening and management of HCC in PLWH and discuss the persisting challenges and disparities in care which may contribute to clinical outcome in PLWH. |
The Emerging Role of Second Harmonic Generation/Two Photon Excitation for Precision Digital Analysis of Liver Fibrosis in MASH Clinical Trials. One SHG/TPE microscopy methodology coupled with AI/ML based analysis, qFibrosis™, has been used post-hoc as an exploratory endpoint in several clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) demonstrating its ability to provide a consistent and more nuanced assessment of liver fibrosis that still correlates well with traditional staging. This review summarizes the development of qFibrosis and outlines the need for additional studies to validate it as a sensitive marker for changes in fibrosis in the context of treatment trials and correlate these changes with subsequent liver-related outcomes. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endoscopy |
| Gastroenterology |
| Gastrointest Endosc |
| Gut |
| Hepatology |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Gastroenterology |
| Gut |
| J Hepatol |